Search Results
Your search for early matches 10130 pages
Showing 6701 - 6750FDA Grants Priority Review to Pembrolizumab for First-Line Treatment of Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the first-line treatment of patients with advanced non–small...
Nivolumab in Recurrent Classical Hodgkin Lymphoma: Refreshingly Supportive Data
It is commonly said that if something is too good to be true, it usually is. It is therefore quite refreshing when really good results are replicated in a subsequent study. As reported in The Lancet Oncology by Younes et al1 and reviewed in this issue of The ASCO Post, a phase II trial of...
ASCO Applauds Bold Recommendations From Cancer Moonshot Blue Ribbon Panel
ASCO commended the Cancer Moonshot Initiative Blue Ribbon Panel for its ambitious recommendations to accelerate progress against cancer. “We applaud the Blue Ribbon Panel for its work and the National Cancer Institute's (NCI's) National Cancer Advisory Board for convening the panel,”...
Nivolumab Achieves Response in Most Patients With Classical Hodgkin Lymphoma After ASCT and Brentuximab Vedotin
In a phase II trial reported in The Lancet Oncology by Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, treatment with the anti–PD-1 (programmed cell death protein 1) immune checkpoint inhibitor nivolumab (Opdivo) produced response in two-thirds of patients with...
Weight Watchers and the American Cancer Society Launch Initiative to Support Holistic Health for Breast Cancer Survivors
Weight Watchers International, Inc, has launched Project LIFT—Live Inspired, Fight Together—a new movement, in collaboration with the American Cancer Society, to inspire and guide breast cancer survivors with free resources focused on tackling the unexpected weight gain that can follow breast...
Multitude of Mentors Help Shape an Illustrious Career in Oncology
Sumanta K. Pal, MD, has had a longer career in oncology than many other colleagues his age. Perhaps the reason for that may center on his starting college at the age 13 and medical school at the age of 17. Today this internationally recognized leader in genitourinary cancers is Assistant Professor ...
Management of Merkel Cell Carcinoma
A recent report regarding pembrolizumab (Keytruda) for advanced Merkel cell carcinoma ushered in a more optimistic era in the treatment of this rare but often lethal skin cancer.1 The ASCO Post spoke with one of the field’s leaders, Paul Nghiem, MD, PhD—the first author of the study—about the...
ASCO 2016: Geriatric Oncology Highlights
Clinical trials focused on older adults with cancer were featured prominently at the 2016 ASCO Annual Meeting. There was a plenary session in glioblastoma, a clinical symposium on immunotherapy, and multiple educational lectures highlighting the growing literature and unique challenges in the...
Interim PET-Adapted Treatment in Advanced Hodgkin Lymphoma
The ability to cure a majority of patients with advanced Hodgkin lymphoma is one of the major milestones of success in the combination chemotherapy era. It has been over 40 years since Bonadonna and colleagues in Milan developed the ABVD regimen (doxorubicin, bleomycin, vinblastine, and...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center found in a report published by Chen et al in Cancer...
Hypofractionated Radiotherapy for Localized Prostate Cancer: A New Standard of Care?
For at least the past quarter of a century, radiobiologists and radiation oncologists have debated the role of hypofractionation (fewer total fractions with a higher dose per fraction) for prostate cancer. The debate stems from the unique radiobiology of prostate cancer and the best means to...
Roundup of Selected Abstracts in Multiple Myeloma, Acute and Chronic Leukemia, and Advanced Lymphoma
In June 2016, the European Hematology Association Congress convened in Copenhagen, Denmark. The educational and scientific program highlighted state-of-the-art clinical practice and the latest findings in hematology research. The ASCO Post brings its readers brief summaries of some of the important ...
For High-Grade and Aggressive Non-Hodgkin Lymphomas, Treat Adults Like Children
Outcomes for adults with high-grade and aggressive non-Hodgkin lymphomas (NHLs) appear to be better when these patients are treated with pediatric-inspired protocols, according to Mitchell S. Cairo, MD, Chief of the Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Maria...
Early-Stage Prostate Cancer Incidence Rates Decline, Distant-Stage Disease Rates Unchanged in 2013
Jemal et al described findings indicating a continued decline in the incidence of localized/regional-stage prostate cancer at 2 years after the U.S. Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) screening in men aged ≥ 50 years in 2011, in a letter ...
Better Overall Survival Reported With FOLFIRI Plus Cetuximab vs Plus Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
In a post hoc analysis of the German phase III FIRE-3 trial reported in The Lancet Oncology, Stintzing et al found that first-line FOLFIRI (fluorouracil, leucovorin, irinotecan) plus cetuximab (Erbitux) was associated with improved overall survival vs FOLFIRI plus bevacizumab (Avastin) in an...
Palliative Care 2016: Early Palliative Care Improves Coping, Quality of Life for Patients With Incurable Cancers
A randomized clinical trial found that introducing palliative care shortly after a diagnosis of certain metastatic cancers greatly increases a patient’s coping abilities, as well as overall quality of life. Researchers also found that early integration of palliative care results in an...
Early Relapse in Follicular Lymphoma: Clinical Trial Data May Guide Management Decisions
Approximately 20% of patients with follicular lymphoma will relapse within 2 years of diagnosis. Although the optimal management of these patients has not been established, clinicians may be guided by data from recent clinical trials, according to Nathan H. Fowler, MD, Associate Professor and...
Gene Overexpression Scoring System May Accurately Predict Patient Response to Cancer Treatments
Researchers at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) identified 14 genes regulating genome integrity that were consistently overexpressed in a wide variety of cancers. They then created a scoring system based upon the degree of gene overexpression. For...
HSD3B1 Allele May Be Associated With Resistance to Androgen-Deprivation Therapy and Poorer Outcome in Prostate Cancer
In a retrospective multicohort study reported in The Lancet Oncology, Hearn et al found that the inherited HSD3B1 (1245C) allele was significantly associated with resistance to androgen-deprivation therapy and poorer outcome in men with prostate cancer. HSD3B1 (1245A>C) has been linked to...
Higher Baseline Metabolic Tumor Volume May Predict Poorer Outcome in Patients With High Tumor Burden Follicular Lymphoma
In a pooled analysis reported in the Journal of Clinical Oncology, Meignan et al found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG PET-CT) was associated with poorer outcome in patients...
Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
In the phase III CASTOR trial reported in The New England Journal of Medicine, Palumbo et al found that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone markedly improved progression-free survival among patients with relapsed or relapsed and refractory...
Novel MRI Technique Distinguishes Healthy Prostate Tissue From Cancer Using Zinc
A novel magnetic resonance imaging (MRI) method that detects low levels of zinc ion can help distinguish healthy prostate tissue from cancer, The University of Texas (UT) Southwestern Medical Center radiologists have determined. The findings were published by Clavijo Jordan et al in the Proceedings ...
Study Finds Chemotherapy May Be Avoidable in Women With Early Breast Cancer at High Clinical but Low Genomic Risk on 70-Gene Signature Assay
In a phase III trial (MINDACT) reported in The New England Journal of Medicine, Cardoso et al found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical risk but low genomic risk as determined by the 70-gene signature assay (MammaPrint)....
Hypofractionated Radiotherapy: Balancing Benefits vs Risks in Men With Localized Prostate Cancer
Radiation for prostate cancer typically requires 40 to 45 daily treatments, given over 8 to 9 weeks. Long fractionation schemes are chosen for most cancers, because they allow for tumor killing while reducing the potential for injury to normal tissue. However, the radiobiology of prostate cancer...
Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer
In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional radiotherapy in disease-free survival...
Melanoma MicroRNA Trafficking May Control Tumor Primary Niche Formation
Researchers at Tel Aviv University (TAU) may have unraveled the metastatic mechanism of melanoma. According to a paper published by Dror et al in Nature Cell Biology, scientists discovered that before spreading to other organs, a melanoma tumor sends out tiny vesicles containing molecules of...
Plasma vs Tissue Genotyping and Outcomes With Osimertinib in Advanced Non–Small Cell Lung Cancer
Patients with advanced non–small cell lung cancer (NSCLC) positive for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor T790M resistance mutation on a plasma assay had similar outcomes with the EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) as did those who were positive ...
Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy
Lucio Crinò, MD, of the University Medical School of Perugia, Italy, and colleagues found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib...
Moffitt Cancer Center Receives Two NCI Grants to Further Prostate Cancer, Biomarker Research
Moffitt Cancer Center researchers recently received two National Cancer Institute (NCI) grants to further research in two areas of study: bone metastasis in prostate cancer and imaging biomarkers for early cancers. Moffitt Cancer Center researchers David Basanta, PhD, and Conor Lynch, PhD, have ...
Supporting Cancer Research Through the Conquer Cancer Foundation
The Conquer Cancer Foundation of ASCO funds the brightest minds in clinical and translational cancer research through its Grants and Awards Program. Since its inception in 1984, the Grants and Awards program has awarded more than $100 million through more than 1,500 grants and awards to at least 65 ...
ASCO, Conquer Cancer Foundation Congratulate 2016 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.1 million in grants and awards to nearly 250 promising oncology researchers at the 2016 ASCO Annual Meeting. The Conquer Cancer Foundation and ASCO congratulate the recipients on their contributions to the field of oncology and...
Erratum
In the July 25 issue of The ASCO Post, the Letter to the Editor titled “Revisiting Ovarian Ablation in Early Breast Cancer: A Mismatch Between Global Values and Clinical Practice Guidelines,” by Richard R. Love, MD, appeared without a complete reference list. The ASCO Post apologizes to Dr. Love...
Clinical Trials Actively Recruiting Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on chronic lymphocytic leukemia. These studies are investigating multiple combination chemotherapies; regimens for relapsed and/or refractory disease; the role of inhibitors;...
Chamomile
Scientific Name: Matricaria recutita, Chamomilla recutita, Matricaria chamomilla Common Names: Hungarian chamomile, wild chamomile Overview An aromatic annual herb prevalent in Europe, North Africa, and Northwest Asia, chamomile has been used as a medicinal plant for several centuries. It has been ...
A Complete Guide to Breast Surgery and Reconstruction
BookmarkTitle: Breast Cancer Surgery and Reconstruction: What’s Right for YouAuthor: Patricia Anstett, with photography by Kathleen GalliganPublisher: Rowman & LittlefieldPublication date: June 2, 2016Price: $35.00; hardcover, 224 pages Over the past 2 decades, we have seen tremendous...
Spotlight on ASCO’s Geriatric Oncology Webpage
With the increasing population of older adults with cancer, there has been a commensurate need for more readily available and widely accessible educational and clinical resources in geriatric oncology. As part of the Cancer and Aging Research Group and ASCO’s Geriatric Oncology Special Interest...
Surgical Oncologist Quan P. Ly, MD, FACS, Flees From Vietnam and Finds a Home at the University of Nebraska
After the Vietnam War, close to a million refugees, known as “boat people,” fled Vietnam, hazarding the open ocean on dangerously overloaded vessels. The term “boat people” is often used generically to refer to all the Vietnamese (about 2 million) who left their country by any means between 1975...
Inotuzumab Ozogamicin Improves Outcomes vs Standard Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
In a phase III trial reported in The New England Journal of Medicine, Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that treatment with the antibody-drug conjugate inotuzumab ozogamicin resulted in a greater complete remission rate and improved ...
Prevalence of Estrogen Receptor Mutations in Patients With Metastatic Breast Cancer
A new study published online by JAMA Oncology examined the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.1 The activation of the estrogen receptor is a feature of most breast cancers in which estrogen receptor expression is detected. An...
ASCO Endorses Cancer Care Ontario Recommendations on Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decisions in Early-Stage, Operable Breast Cancer
As reported in the Journal of Clinical Oncology (JCO) by N. Lynn Henry, MD, PhD, of University of Michigan Comprehensive Cancer Center, Ann Arbor, and colleagues,1 ASCO has endorsed Cancer Care Ontario guideline recommendations on the role of patient and disease factors in decisions on adjuvant...
Indiana University School of Medicine Receives $2 Million Gift
The children of Indianapolis philanthropists Sidney and Lois Eskenazi have made a $2 million gift to the Indiana University School of Medicine to be used to recruit a highly accomplished researcher focused on discovering new ways to treat, diagnose, and prevent cancer. The gift, to honor their...
Increased Uveal Melanoma Risk Linked to Pigmentation Genes That Dictate Eye Color
New research links specific inherited genetic alterations to an increased risk for uveal melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. These findings were published by Ferguson et al in Scientific Reports. Previous clinical data suggests uveal melanoma...
ASTRO Awards $275,000 in Grants to Support Early Career Researchers in Radiation Oncology
The American Society for Radiation Oncology (ASTRO) has selected four early career scientists to receive a total of $275,000 in research awards, including one winner of the ASTRO Junior Faculty Career Research Training Award and three recipients of ASTRO Resident/Fellows in Radiation Oncology...
Understanding Double-Hit Lymphomas and Optimizing Management
Double-hit lymphomas are a challenging subset of high-grade B-cell lymphomas, previously characterized histologically as diffuse large B-cell lymphoma or B-cell lymphoma unclassifiable with intermediate features between diffuse large B-cell lymphoma and Burkitt lymphoma. Expert guidance in their...
GADOLIN and the Perplexing Role of Obinutuzumab in the Treatment of B-Cell Malignancies
After several dose-finding phase I and II studies in a variety of B-cell malignancies, the potential clinical role of the newer anti-CD20 monoclonal antibody obinutuzumab (Gazyva) remained unclear. These early trials tested low and high doses as well as weekly and every-3-week schedules of...
Phase III Trial Shows Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Laurie H. Sehn, MD, Chair, British Columbia Cancer Agency Lymphoma Tumor Group, and Clinical Associate Professor at the University of British Columbia, Vancouver, and colleagues, found that adding the anti-CD20 antibody obinutuzumab...
Late Cardiac Effects of Cancer Treatment
The combination of more precise diagnostic tools and advances in surgery, chemotherapy, radiation therapy, and targeted therapy in the treatment of cancer has led to unprecedented numbers of cancer survivors in the United States—more than 15.5 million, according to the latest figures from the...
AACR, Pancreatic Cancer Action Network Awards Research Grants to Early-Career Investigators
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network awarded nine grants to outstanding scientists who will undertake novel research in the field of pancreatic cancer. “By recruiting the brightest scientists with the most novel ideas, we continue to build a ...
AACR Holds Congressional Briefing to Reiterate Moonshot Goals and Plans
“We are in an era of unprecedented scientific opportunities in cancer research,” said Margaret Foti, PhD, MD (hc), Executive Officer, American Association for Cancer Research (AACR), as she introduced the Congressional briefing, “Seizing Today’s Opportunities to Accelerate Cancer Research.” “Thanks ...
New Preclinical Study Shows Esophageal Cancers Driven by 'Marginal Gain' Rather Than Speed
Wellcome Trust Sanger Institute scientists have shown that unexpectedly, esophageal cancer cells do not divide faster than their normal neighbors. Unlike normal cells, however, the tumor cells produce slightly more dividing daughter cells than nondividing cells, forming a tumor. The study,...
